Compounds and compositions as protein kinase inhibitors
AssigneeArray BioPharma Inc.
InventorsShenlin Huang, Xianming Jin, Zuosheng Liu, Daniel Poon, John Tellew, Yongqin Wan, Xing Wang, Yongping Xie
Life of this patent
Estimating the term…
Abstract
The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf.
Claims20
A method of treating melanoma in a subject in need thereof, the method comprising:
- (a) detecting a mutant BRAF kinase in the melanoma;
- and
- (b) orally administering to said subject a therapeutically effective amount of:
- (i) a pharmaceutical composition comprising methyl N-[(2S)-1-({4-[3-(5-chloro-2-fluoro-3-methanesulfonamidophenyl)-1-(propan-2-yl)-1H-pyrazol-4-yl]pyrimidin-2-yl}amino)propan-2-yl]carbamate or a pharmaceutically acceptable salt thereof;
- and
- (ii) a pharmaceutical composition comprising a MEK inhibitor.
The method of 9, wherein said pharmaceutical composition comprising methyl N-[(2 S)-1-({4-[3-(5-chloro-2-fluoro-3-methanesulfonamidophenyl)-1-(propan-2-yl)-1H-pyrazol-4-yl]pyrimidin-2-yl}amino)propan-2-yl]carbamate or a pharmaceutically acceptable salt thereof is formulated as a capsule.
Dependencies are inferred from the claim text.